Latest / Pharmacy Podcast Network / Perfecting Peds x DoseMeRx: Custom Care Conversations | Pediatric Pharmacist Review
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
- 0:28Speaker 2: Adverse drug reactions or ADRs, are a serious issue in
- 0:32Speaker 2: healthcare today. The pharmacist is the last line of defense
- 0:35Speaker 2: to help prevent ADRs. A rising role of the pharmacist
- 0:39Speaker 2: is the specialist who focuses on our children. Pediatric pharmacy
- 0:43Speaker 2: ensures safe and effective drug use and optimal medication therapy
- 0:47Speaker 2: outcomes and children up to eighteen years of age. Currently,
- 0:50Speaker 2: there are more than one four and fifty board certified
- 0:54Speaker 2: pediatric pharmacy specialists known as bps. If you're interested in
- 0:58Speaker 2: this expanding field of pharmacy, this podcast.
- 1:01Speaker 1: Is for you.
- 1:02Speaker 2: All right, everyone, let's give it up for our host.
- 1:06Speaker 3: Hey, listeners, welcome back to the Pediatric Pharmacist Review. I'm
- 1:10Speaker 3: one of your hosts, Justin Cole, and I'm excited to
- 1:13Speaker 3: be co hosting with Jenna Quinn again. Jenna, how you
- 1:15Speaker 3: been great?
- 1:17Speaker 1: Thank you, and thank you guys for joining us and listening.
- 1:20Speaker 1: As always, I'm very excited about this episode.
- 1:23Speaker 3: Yeah, i am too. Today we've got Charmine Roy with us.
- 1:26Speaker 3: She is the chief strategy and Science officer for dose ME.
- 1:30Speaker 3: So we're going to talk a bit about their product,
- 1:32Speaker 3: dose Merx and how this can be used to transform
- 1:35Speaker 3: the health of pediatric patients and so many others as well.
- 1:38Speaker 3: So Charmin, thanks for joining us today.
- 1:41Speaker 4: Thanks Justin. I'm really really happy to be here. You know,
- 1:44Speaker 4: I love I'm a pediatric pharmacist at heart, no matter
- 1:47Speaker 4: what I do with my current role, so I you know,
- 1:50Speaker 4: I love speaking to other pediatric clinicians.
- 1:53Speaker 3: Yeah, we're excited. So with that, why don't you tell
- 1:55Speaker 3: us a bit more about your background and how you
- 1:58Speaker 3: ended up founding and being a part of the team
- 2:00Speaker 3: at dose ME.
- 2:02Speaker 4: Oh that's a really long story, ready to hear. I've
- 2:07Speaker 4: been practicing for way too long, way too long to mention,
- 2:11Speaker 4: I guess I should say. But you know, I've been.
- 2:14Speaker 4: Like I said, I was trained as a clinical pharmacist
- 2:17Speaker 4: in pediatrics, specialized in pediatrics. That was kind of my
- 2:21Speaker 4: my area of expertise and where I practiced for many,
- 2:24Speaker 4: many years, specifically in pediatric critical care. So pick you cardiac,
- 2:28Speaker 4: I see you. I see Jenna shaking because I think
- 2:31Speaker 4: we share that in common. So I've been, you know,
- 2:35Speaker 4: I practiced that for quite some time, and then purely
- 2:40Speaker 4: for weather reasons, my husband I decided to relocate to Miami, Florida,
- 2:46Speaker 4: which is where I reside now. So you know, there
- 2:49Speaker 4: things had to change. I had to, you know, I left.
- 2:53Speaker 4: I think I had done enough in my position at
- 2:56Speaker 4: University of Chicago where I was practicing, you know, building
- 3:00Speaker 4: the pharmacy clinical program, pediatric pharmacy program, really growing that team.
- 3:06Speaker 4: We also developed a pediatric PGY two residency there and
- 3:11Speaker 4: so you know, did quite a bit and establish a
- 3:14Speaker 4: lot of policies and procedures and all the things that
- 3:17Speaker 4: you need to do for that are very special to pediatrics.
- 3:22Speaker 4: But you know, when I relocated, I couldn't really let
- 3:26Speaker 4: go of pediatrics, right, I still wanted to be involved
- 3:29Speaker 4: with it. So I was doing two things. I joined
- 3:33Speaker 4: a startup at that time, Pipeline RX, which was a
- 3:37Speaker 4: telepharmacy company, so providing clinical pharmacy services to rural hospitals,
- 3:42Speaker 4: which is how it initially started. But then we expanded
- 3:45Speaker 4: to quite a bit of other areas, like you know,
- 3:48Speaker 4: clinical support, helping teams transition from paper to uh you know,
- 3:55Speaker 4: electronic health record shanet. You probably have never practiced in
- 3:59Speaker 4: an in vironment where there's paper, but believe it or not,
- 4:02Speaker 4: that's how we did everything before, so, you know, helping
- 4:06Speaker 4: in various aspects and just kind of growing. I was
- 4:09Speaker 4: I think part of two three pharmacists at that time.
- 4:12Speaker 4: That company obviously grew and the team grew to I
- 4:15Speaker 4: think there's over like two hundred pharmacists now, so quite
- 4:19Speaker 4: a bit. But I kept kind of prn helping at
- 4:23Speaker 4: the children's hospital here in Miami. So at the time
- 4:26Speaker 4: it was called Miami Children's Hospital and now it's Nicholas
- 4:28Speaker 4: Children's Hospital, and you know, helped kind of with the
- 4:33Speaker 4: clinical staff. Again. Even there we were going from one,
- 4:36Speaker 4: you know, one ehr to another, so got to get
- 4:40Speaker 4: involved with that, you know, how cutovers go for that,
- 4:42Speaker 4: for that stuff, and then helped to develop the research
- 4:47Speaker 4: operations there essentially you know, pharmacy support for research trials.
- 4:51Speaker 4: That was something that they wanted to really expand on
- 4:54Speaker 4: and grow. So did that for a while, and then
- 4:59Speaker 4: COVID happened and things changed. I made a leap to
- 5:04Speaker 4: staying with research, but in adults and in oncology, which
- 5:08Speaker 4: was quite different. But I knew how to you know,
- 5:11Speaker 4: I knew the research part right, the research operations, so
- 5:14Speaker 4: I had to learn that oncology. So it was funny
- 5:17Speaker 4: when the pharmacists who trained me, I had to tell
- 5:19Speaker 4: her that pretend like I'm a new pharmacist and train
- 5:23Speaker 4: me as a new pharmacist because while I know oncology,
- 5:26Speaker 4: I just obviously need to really kind of get a
- 5:29Speaker 4: better grasp on what was happening currently. So I did
- 5:33Speaker 4: that during COVID. It was quite challenging. It was Miami
- 5:37Speaker 4: Cancer Institute, it was oncology center, so you could imagine
- 5:41Speaker 4: the you know, precautions we had to take there and
- 5:47Speaker 4: challenges we dealt with there. So I was there for
- 5:49Speaker 4: some time and then after that, I in two it's
- 5:52Speaker 4: going to be three years. Hard to believe, but I
- 5:56Speaker 4: joined dose me at the time, and I as a
- 6:00Speaker 4: clinical you know, sort of overseeing our clinical solutions and
- 6:04Speaker 4: service support. And we've transitioned from being part of a
- 6:09Speaker 4: large company to you know a kind of independently owned
- 6:14Speaker 4: software company, and so, you know, we transition to different
- 6:18Speaker 4: roles and now I currently serve as the chief Strategy
- 6:20Speaker 4: and Science Officer, where I oversee our CX, which is
- 6:24Speaker 4: customer support, implementation, onboarding, and the science team, so everything
- 6:29Speaker 4: behind the platform and the product. So I told you
- 6:33Speaker 4: it was a long story and you can set out
- 6:35Speaker 4: whatever you need to.
- 6:36Speaker 1: Oh no, we love it.
- 6:38Speaker 4: We love it.
- 6:39Speaker 1: My husband calls me Oprah because I love to know
- 6:43Speaker 1: like everyone's backstories, backstories and deep, deep life experience. So no,
- 6:49Speaker 1: this is perfect. This is right up my alley.
- 6:52Speaker 4: So Seannette, the lesson is, don't worry about taking the
- 6:56Speaker 4: traditional path. You just never know what opportunities will come,
- 7:00Speaker 4: you know, just because you just never you just never know.
- 7:02Speaker 4: You don't want to kind of, you know, narrow your
- 7:04Speaker 4: focus when you're seeing what's out there. So that's that's
- 7:09Speaker 4: what I always tell the students.
- 7:11Speaker 1: It's so true. And Sewn is one of our students
- 7:14Speaker 1: here from l Iu. We have had the pleasure of
- 7:18Speaker 1: perfecting peds to have about five or six students on
- 7:21Speaker 1: rotation for folks, So it's like five or six students
- 7:25Speaker 1: for five or six weeks and it's been really cool
- 7:28Speaker 1: and charman to that point, I always stress similarly, you
- 7:33Speaker 1: never know your path. It might not only be pharmacy.
- 7:36Speaker 1: Keep your eyes open. I always do tell them too,
- 7:39Speaker 1: like I was the most average student, like borderline terrible,
- 7:44Speaker 1: and so I feel like they need to hear that too,
- 7:47Speaker 1: because like, pharmacy school's so cut through and you feel like, Okay,
- 7:50Speaker 1: if I'm an average student, does that mean that you
- 7:53Speaker 1: know my career is going to be average? And it
- 7:56Speaker 1: doesn't equate And so you know, it took me a
- 7:59Speaker 1: while to kind of get filled up my confidence after
- 8:02Speaker 1: a pharmacy school because I was so average. So again,
- 8:08Speaker 1: but you have no idea where life's going to take you,
- 8:10Speaker 1: shout out, So keep your keep your eyes open. But
- 8:15Speaker 1: I would love to know and a little bit more
- 8:18Speaker 1: about your platform and Charmine and I had like an
- 8:20Speaker 1: introductory call like two years ago, and so this is
- 8:25Speaker 1: exciting to catch up to see what growth has happened
- 8:28Speaker 1: at dose me, which I'm assuming is a ton, But
- 8:32Speaker 1: can you hone in on a little bit about what
- 8:34Speaker 1: are the most important thing to us? Of course, the
- 8:37Speaker 1: pediatric care and how dose me is useful at improving
- 8:42Speaker 1: the health outcomes of the pediatric population.
- 8:46Speaker 4: Sure, yeah, and I think all of us can agree
- 8:50Speaker 4: there's this never enough you know, pediatric data, there's not
- 8:53Speaker 4: enough research that's being done even when you know drugs
- 8:56Speaker 4: get approved right pediatric now, I think because of all
- 9:00Speaker 4: the push from the FDA they do do studies to
- 9:04Speaker 4: you know, kind of determine dosing. But I remember being
- 9:08Speaker 4: in the pick. You taking care of very very sick kids,
- 9:11Speaker 4: and you know, you're using drugs that are only approved
- 9:13Speaker 4: in adults, but you have to kind of figure out
- 9:15Speaker 4: the dosing or find some obscure case report from you know,
- 9:20Speaker 4: some hospital that used that drug and you have to
- 9:24Speaker 4: kind of say, okay, well it worked for them, let's
- 9:26Speaker 4: try this dose, or let's you know, just I don't know,
- 9:30Speaker 4: use all the PK parameters and figure out a dose
- 9:33Speaker 4: and hope that you're right. So I think that's been
- 9:36Speaker 4: a challenge for pediatric clinicians, you know, for even for adults. Right.
- 9:40Speaker 4: So in certain depending on the drug, if it's a
- 9:43Speaker 4: neurotherapeutic window drug, you have to kind of figure out
- 9:47Speaker 4: what the appropriate doses, and everybody is metabolizing it differently.
- 9:53Speaker 4: You all know from kind of the work that you
- 9:55Speaker 4: do that there's so much variability in pediatrics and what
- 9:58Speaker 4: they response respond to and how they respond to it.
- 10:01Speaker 4: So you know, one of the nice things that the
- 10:04Speaker 4: dose Mirx does for pediatric patient is like it's really
- 10:08Speaker 4: adapting to the patient. Right, So I know we'll talk
- 10:11Speaker 4: more delve more deeply into how the models work and
- 10:15Speaker 4: how it adapts. But really it's you know, incorporating patient
- 10:20Speaker 4: data into dosing and taking in whether it's the you know,
- 10:24Speaker 4: antibiaut microbil level that's being monitored or the patient's renal
- 10:28Speaker 4: function and incorporating that and really adapting to the patient
- 10:32Speaker 4: and you can sort of, you know, with confident do
- 10:37Speaker 4: go move forward with dosing knowing that okay, it's predicting
- 10:40Speaker 4: this outcome, it's predicting you know, this exposure level to
- 10:43Speaker 4: the patient. So you're using more information. So the math
- 10:47Speaker 4: is we all know the math, right, it exists. You
- 10:49Speaker 4: can do it. It's hard, it takes time. If you're
- 10:53Speaker 4: in the piqu you have thirty beds that you're taking
- 10:55Speaker 4: care of, you know, not always able to do that quickly.
- 10:58Speaker 4: So it's really just making that kind of clinical workflow
- 11:02Speaker 4: easier for clinicians so they can do the most appropriate
- 11:07Speaker 4: dosing and adjusting of dosing based on the patient's response.
- 11:12Speaker 4: So that's really kind of how dose Merx helps the
- 11:17Speaker 4: clinician with the outcomes. Right. So outcomes are very tricky
- 11:20Speaker 4: because it's not one thing that leads to an outcome.
- 11:23Speaker 4: It's multiproced, and so it's helping that clinician make the
- 11:27Speaker 4: best judgment and decision based on all the factors they're
- 11:30Speaker 4: looking at and what the platform is providing as a
- 11:34Speaker 4: kind of a guidance to dosing. Yeah.
- 11:39Speaker 3: Sure, I mean, as pediatric pharmacists, we all know how
- 11:41Speaker 3: important therapeutic drug monitoring is to tailoring in those doses
- 11:45Speaker 3: for each of our kids. So dose Merx seems like
- 11:48Speaker 3: a fantastic platform to help with that. So let's go
- 11:52Speaker 3: ahead and get into the weeds a little bit more. So,
- 11:54Speaker 3: can you explain to us how dose me rx actually works,
- 11:57Speaker 3: how do pharmacists interact with it, and maybe you could
- 12:01Speaker 3: even walk us through an example drug that can be
- 12:03Speaker 3: used in pediatric patients and how dose Marx can tailor
- 12:06Speaker 3: therapeutic drug monitoring.
- 12:09Speaker 4: Yeah. You know, the funny thing is that it takes
- 12:13Speaker 4: less convincing for pediatric clinicians to use it than adult clinicians.
- 12:18Speaker 4: So that's good because we know that everything needs to
- 12:20Speaker 4: be tailored, right, We're taking care of like newborns to
- 12:24Speaker 4: adolescents and almost adults, so we know the variability and
- 12:27Speaker 4: the changes we have to kind of incorporate into the
- 12:31Speaker 4: dosing and so that's an easier sell almost, you know,
- 12:35Speaker 4: I don't have to convince them as much. Precision dosing
- 12:37Speaker 4: is something I always tell people. It's not a fancy word,
- 12:40Speaker 4: but pharmacists that have been practicing at pedes have been
- 12:43Speaker 4: doing precision dosing. That's what they do. And so the
- 12:48Speaker 4: models we have in our platform, so you know, majority
- 12:52Speaker 4: of therapeutic drug monitoring happens like in antimicrobials, right, So
- 12:56Speaker 4: I'll use vankomycin aminoglycosides for peds, it's a lot more
- 13:00Speaker 4: amino glycosides. So those are some of the medications that
- 13:04Speaker 4: get commonly utilized. And the way the platform works is
- 13:07Speaker 4: it's it's a Bayesian modeling software. So it takes published,
- 13:12Speaker 4: peer reviewed validated models we implemented in our in our software,
- 13:17Speaker 4: and it takes those PKPD models and estimates the outcome
- 13:23Speaker 4: based on the patient data. So it's think of it
- 13:25Speaker 4: as the original sort of starting point is the baseline model.
- 13:29Speaker 4: Then you have the patient's information that's incorporated into the
- 13:32Speaker 4: model calculations, and so it over times individualizes the dosing.
- 13:37Speaker 4: So once you get you know, let's use Vanko micon
- 13:42Speaker 4: as an example. You know, the guidelines had changed it's
- 13:47Speaker 4: going to be now five years, believe it or not,
- 13:49Speaker 4: but had changed to AAC guided Yeah, AAC guided dosing.
- 13:53Speaker 4: So that is not as easy to do than just
- 13:57Speaker 4: you know, looking at peaks and troughs and adjusting and
- 14:00Speaker 4: doing calculations that way. So you know, taking banko mice
- 14:04Speaker 4: and you get you still you can get the level
- 14:07Speaker 4: from the patient and incorporates renal function patients concentration, and
- 14:12Speaker 4: then adjust the modeling prediction based on that and the
- 14:15Speaker 4: algorithms that are incorporating.
- 14:19Speaker 1: That's really cool and I that dates me because I
- 14:23Speaker 1: remember I was just leaving that I see you as
- 14:26Speaker 1: we were starting to use the AUC dosing. But then
- 14:31Speaker 1: add the added confusion to other providers outside of pharmacist
- 14:36Speaker 1: that it's a different equation to estimate the GFR for
- 14:41Speaker 1: pediatric patients. So that that's obviously and you know you
- 14:45Speaker 1: you when you mentioned the bedside swords, people are like,
- 14:48Speaker 1: what is that? So I think that's awesome that you're
- 14:53Speaker 1: having pediatricians buying gear product. Does me a integrate into
- 15:01Speaker 1: any current EHRs.
- 15:03Speaker 4: Yeah, so you know, we always have this the goal
- 15:07Speaker 4: to make it available to everybody, right, so there will
- 15:10Speaker 4: be hospitals that just want the web application, where you know,
- 15:13Speaker 4: in my opinion, it's always more time consuming because you're
- 15:16Speaker 4: manually in putting information. There's higher risk for you know,
- 15:20Speaker 4: input error or data entry error. But it's EHR agnostics,
- 15:24Speaker 4: so it integrates with any EHR that can have that,
- 15:27Speaker 4: you know, standard fire API application. I know, I'm a
- 15:31Speaker 4: I'm not a deaf person, but that's like the extent
- 15:33Speaker 4: of my knowledge of integration. But yeah, we so startin
- 15:37Speaker 4: our epic. Some of the surveillance software is actually like
- 15:41Speaker 4: Vigilance and Century seven, So you know, whatever is already
- 15:44Speaker 4: incorporated into the the pharmacist workflow, it will integrate if
- 15:49Speaker 4: that's the route that you know, any system or hospital
- 15:52Speaker 4: wants to go through. The nice thing with that is
- 15:54Speaker 4: that you don't have to input anything. So if it's
- 15:57Speaker 4: integrated with your EHR, you pull up the patient's chart,
- 16:00Speaker 4: you launch dose me, and it will provide the most
- 16:02Speaker 4: current information about the patient, whether it's the doses that
- 16:05Speaker 4: are given, you know, lab values, serum creating values, patient
- 16:11Speaker 4: demographic all that automatically populates. So it just makes everything
- 16:14Speaker 4: more seamless and the workflow a little bit easier.
- 16:18Speaker 3: Sure, I mean does dose. MERX also help to streamline
- 16:22Speaker 3: the documentation process for the person that's completing the pharmacokinetic calculations,
- 16:26Speaker 3: Like does it give you all of the outputs but
- 16:30Speaker 3: also put those in a way that could easily be
- 16:32Speaker 3: translated to documentation.
- 16:35Speaker 4: Yeah, so it does generate a report that can so
- 16:39Speaker 4: if you're integrated that that's actually the really nice thing
- 16:42Speaker 4: that you don't have to kind of copy paste and
- 16:45Speaker 4: transfer into a template. If you are integrated into the EHRs,
- 16:50Speaker 4: you can just hit you know, like there's at the
- 16:52Speaker 4: end of the calculation, you can hit generate report and
- 16:55Speaker 4: it will send a progress note back to the EHR,
- 16:58Speaker 4: which just cuts down so much time and also again
- 17:02Speaker 4: making sure you're not cutting and pasting and having to format,
- 17:04Speaker 4: Like that's just tasks that we don't need to waste
- 17:07Speaker 4: time on, right, So that's a really nice thing about.
- 17:10Speaker 3: It, Jenna if and for you, Charmine, I'm sure we
- 17:14Speaker 3: can think back to times when we were in the
- 17:16Speaker 3: hospital where we might have spent as much time on
- 17:19Speaker 3: our note as we did on the calculations, right, I mean,
- 17:21Speaker 3: it just is one of those tedious tasks that takes
- 17:25Speaker 3: a clinician's time, and so I love that dose MERX
- 17:28Speaker 3: has decreased some of that cognitive demand and task related
- 17:33Speaker 3: work for the pharmacist, lets us do things that we
- 17:35Speaker 3: really need to focus on. So I love that. That's fantastic.
- 17:39Speaker 4: Yeah, And that's essentially it, right, like bringing it to
- 17:42Speaker 4: the bedside that you know, just making it easier. So
- 17:45Speaker 4: when you're rounding with your team and you get a
- 17:48Speaker 4: level that comes back while you're rounding, you can quickly
- 17:52Speaker 4: change the dose and adjustin do what you need to
- 17:54Speaker 4: right there at the bedside, and it quickly calculates it.
- 17:56Speaker 4: You don't have to make a note. I mean, I
- 17:58Speaker 4: remember those days, make a note, go back, do all
- 18:00Speaker 4: your calculations, you know, manually, and then come back and
- 18:04Speaker 4: put the note in or change the dose or get
- 18:06Speaker 4: a hold of the resident that needs to change it.
- 18:08Speaker 4: So it's just, you know, the less we need to
- 18:11Speaker 4: do of those kinds of tests, the better.
- 18:13Speaker 1: Yeah, I mean, And we're we live at a at
- 18:16Speaker 1: a fun age where you know, we can use AI
- 18:19Speaker 1: to our advantage, not to replace us, but just help
- 18:22Speaker 1: expedite everything that we do. And like you're saying, like
- 18:25Speaker 1: we're working with a perfecting PiZZ Like how do we
- 18:30Speaker 1: use technology to cut down our note taking time because
- 18:33Speaker 1: it is it's like one of the most painful dants,
- 18:36Speaker 1: but it's necessary because like if you don't have good communication,
- 18:41Speaker 1: if they flip between we're communicating out to other providers, obviously,
- 18:45Speaker 1: that could be fatal. So that's really cool that you
- 18:49Speaker 1: guys integrate into all the EHRs and now that we're
- 18:52Speaker 1: building our own technology here called our ex junior, I
- 18:55Speaker 1: can actually keep up with the lingo there again, very out,
- 19:00Speaker 1: very service level.
- 19:02Speaker 4: That's the fun part, you know. You I think that's
- 19:07Speaker 4: that is like the superpower pharmacist, that there's so many
- 19:10Speaker 4: things that we can do, right, So it's taking care
- 19:14Speaker 4: of patients of course, look, you know reviewing medications, those
- 19:18Speaker 4: are our expertise, but you know, all these non traditional
- 19:22Speaker 4: kind of roles and learning about technology and how to
- 19:25Speaker 4: incorporate it. I mean, I remember when a UFC when
- 19:29Speaker 4: we had to implement we were going from the conversion
- 19:32Speaker 4: to epic. You know, there was no pediatric dosing, brain
- 19:37Speaker 4: checking or any of that. Like I had to really
- 19:39Speaker 4: work with our team to build those tables. And so
- 19:43Speaker 4: I think there's just we're just kind of at the
- 19:45Speaker 4: core of so many things that it's just kind of
- 19:47Speaker 4: nice to see pharmacists in all these different roles doing
- 19:51Speaker 4: you know, really cool work and it doesn't have to
- 19:53Speaker 4: be what you know you went to school for or
- 19:55Speaker 4: maybe you thought you were going to do. But you know,
- 19:58Speaker 4: all that is important, right, like all the things, those administratives,
- 20:01Speaker 4: the notes, it's important to know how to write those
- 20:05Speaker 4: should things fail, right, because that happens too. But but yeah,
- 20:09Speaker 4: that's definitely taking that away. I won't miss it meybe neither.
- 20:15Speaker 1: Yeah, So is there dis dose me have certain medications
- 20:21Speaker 1: or I know you already discussed banco and gentimizing, so
- 20:27Speaker 1: maybe just focus on the health conditions that you feel
- 20:31Speaker 1: like are the highest sutilization health conditions for do's mi RX. Yeah,
- 20:37Speaker 1: so just taking a step back to the medications. I
- 20:41Speaker 1: was so we you know, we our platform gets used
- 20:45Speaker 1: kind of in the US as well as outside, so
- 20:48Speaker 1: internationally cool. And the cool thing about that is that
- 20:52Speaker 1: I get to see how all these different pharmacists pharmacologists
- 20:55Speaker 1: practice and use the platform in different settings. So we have,
- 20:59Speaker 1: you know, a lot of models. It's not just the
- 21:02Speaker 1: vankomcin and immine glycosides. We have antipolyptics, there's oncology, drugs.
- 21:08Speaker 1: You know, there's various other beta laftams as well, and
- 21:11Speaker 1: so I would say outside of the US that they
- 21:14Speaker 1: get utilized more than in the US. It's more focused
- 21:18Speaker 1: on antimicrobials because it's it's where I think it's because
- 21:25Speaker 1: the guide where the guidelines drive practice as well as
- 21:29Speaker 1: if it's required, you know, therapeutic drug monitoring. While pedes
- 21:34Speaker 1: pharmacists are very used to doing it and let's just
- 21:37Speaker 1: get a level to figure out what's going on with
- 21:39Speaker 1: this patient. People don't really like doing therapy, you know,
- 21:43Speaker 1: especially in the adult world. It's like if you if
- 21:46Speaker 1: you can avoid it, they will so, but you know,
- 21:50Speaker 1: the focus is on those medications that have the neuro
- 21:54Speaker 1: therapeutic index, right, so you really want to make sure
- 21:57Speaker 1: you get to that goal levels. Mostly it's most mostly
- 22:04Speaker 1: used for anti microbials, but we do, like I mentioned,
- 22:07Speaker 1: have some oncology drugs like BUE sulfon for example, that's
- 22:11Speaker 1: used quite a bit in PEATZ population, in the leukemia population.
- 22:16Speaker 1: So that's actually another model that we're seeing a growth
- 22:20Speaker 1: in the use of it in the.
- 22:22Speaker 4: US as well. Because p K was always done for
- 22:24Speaker 4: BUE self in but it was always sort of like
- 22:26Speaker 4: outsourced sort of speak, so it would go to a
- 22:29Speaker 4: lab and somebody else would help you do the kinetics.
- 22:31Speaker 4: But I think with a lot of things that happened
- 22:34Speaker 4: during COVID and you know the logistics challenges, so I
- 22:38Speaker 4: think a lot of institutions are bringing in house those
- 22:41Speaker 4: level monitoring, so they need a software to be able
- 22:44Speaker 4: to do the dosing right. So oncology is a space
- 22:47Speaker 4: that's growing and it continues to grow because I think
- 22:50Speaker 4: there's a lot of data and evidence coming out that
- 22:53Speaker 4: you need really need to monitor some of those medications
- 22:56Speaker 4: to make sure that you're having the optimal exposure and
- 22:59Speaker 4: the best comes. So those are I would say those
- 23:02Speaker 4: are kind of the big categories. But I think as
- 23:06Speaker 4: people are becoming more comfortable with using a software, so
- 23:10Speaker 4: you know, it's like they try with the PEEDS. It's
- 23:13Speaker 4: actually interesting so the PEEDS clinicians, because the guidelines didn't
- 23:16Speaker 4: really go into too much detail. They covered the peed's patients,
- 23:21Speaker 4: but they didn't go into too much detail. I think
- 23:22Speaker 4: they were kind of letting the adults figure it out.
- 23:25Speaker 4: So we're now seeing not now. I say, like last year,
- 23:29Speaker 4: I started seeing more and more pediatric institutions like implementing
- 23:33Speaker 4: this and really officially kind of converting over to AUC
- 23:36Speaker 4: because there's comfort level, there's more evidence. You know, they're
- 23:40Speaker 4: trying to see how how they can make sure that
- 23:43Speaker 4: they're kind of you know, being compliant with the guidelines
- 23:47Speaker 4: and also expanding to other areas, so things like warfarin
- 23:51Speaker 4: and you know, transplant drugs like tacrow. So there's expansion
- 23:57Speaker 4: in those areas now that there's an increase in comfort level.
- 24:00Speaker 4: So those are kind of the main areas I would
- 24:02Speaker 4: say now, but it has more experienced clinicians get more
- 24:07Speaker 4: comfortable with it. I think they're trying to expand its
- 24:10Speaker 4: use for sure.
- 24:11Speaker 1: Yeah, I mean I'm looking at your website now and yeah,
- 24:14Speaker 1: it's it's exciting to see what's the amount of drugs
- 24:18Speaker 1: that you have in review and in development. There's there's
- 24:22Speaker 1: a lot, and you know, we see so many children
- 24:29Speaker 1: with the anti convulsions and so just just exciting to
- 24:33Speaker 1: see what you guys got going to pipeline. It's a lot.
- 24:36Speaker 4: Yeah, and I'm biased towards Pete, so I always make
- 24:39Speaker 4: sure that we're always including that cohort. So we actually
- 24:42Speaker 4: just you know, recently, you know, added voricanosol pediatrics another
- 24:48Speaker 4: neonatal model, So you know, just always kind of listening
- 24:52Speaker 4: to the customer, right, which is the pharmacist, like, what
- 24:55Speaker 4: are their other challenges. So one of the areas, you know,
- 24:59Speaker 4: kind of one of the first things we did was
- 25:01Speaker 4: implement a second pediatric model when I after shortly after
- 25:05Speaker 4: I joined, and that was because you know, it's the
- 25:08Speaker 4: unfortunate truth that patients pediatric patients we have more We're
- 25:12Speaker 4: seeing more and more obese pediatric patients and so dosing
- 25:16Speaker 4: is very challenging for those patients because there's just no data.
- 25:19Speaker 4: So a lot of our pharmacists were like, well, the
- 25:22Speaker 4: current model, we can't really use it for those patients
- 25:24Speaker 4: because it you know, there's limitations to each model, and
- 25:27Speaker 4: we can't really recommend going outside of this, although I
- 25:30Speaker 4: will say pharmacists get curious and they will try. So
- 25:36Speaker 4: we implemented a second model to cover that cohort and
- 25:38Speaker 4: make sure that it's what you know, it's a wider
- 25:40Speaker 4: cohort to include pediatric obese patients, so when that is
- 25:43Speaker 4: a patient you're taken care of, you can easily dose
- 25:46Speaker 4: those patients. Similarly, we've added a second neonate model for
- 25:50Speaker 4: vankom isocin just to give another option, because not every
- 25:54Speaker 4: patient fits every model, and so just giving that those
- 25:57Speaker 4: options are are just really beneficial for the clinicians. And yeah,
- 26:02Speaker 4: so I always kind of make sure that when we're
- 26:04Speaker 4: looking at drugs, we're always thinking about, you know, all
- 26:07Speaker 4: the all the cohorts and making sure that pediatrics are included.
- 26:12Speaker 3: Way to keep advocating for pediatric patients and making sure
- 26:15Speaker 3: we've got all that we need to support them. Well, Charmine,
- 26:18Speaker 3: you mentioned that, of course, all of your models that
- 26:20Speaker 3: dosed me rx are based on published studies and pharmacokinetic
- 26:24Speaker 3: parameters that have been validated. So maybe you could peel
- 26:28Speaker 3: back the curtain a little bit and tell us how
- 26:31Speaker 3: does your team go about finding that data, creating your models,
- 26:35Speaker 3: and then validating them for clinical practice. What does some
- 26:39Speaker 3: of that work look like behind the scenes.
- 26:41Speaker 4: Yeah, so I have a really really smart science team
- 26:44Speaker 4: that does a lot of that review. Initially, when we
- 26:48Speaker 4: you know, either get our request from a customer or
- 26:50Speaker 4: we know that something's changing where it would be really
- 26:53Speaker 4: helpful to say, have you know voriconos all for example
- 26:57Speaker 4: level right, So they go through a pretty rigorous process
- 27:02Speaker 4: to identify validate clinical you know, published and validated model.
- 27:07Speaker 4: Once we implement it in our system, we go through
- 27:10Speaker 4: external validation that we collaborate with, just because we want
- 27:15Speaker 4: to make sure that we're not really implementing something and
- 27:18Speaker 4: not having you know, anybody validate that it's actually correctly implemented, right,
- 27:22Speaker 4: so independently gets validated, and then the clinical validation really
- 27:26Speaker 4: just happens once the clinicians start using it. Everybody has
- 27:30Speaker 4: a different approach. We don't really dictate that because it
- 27:32Speaker 4: has to suit their needs, right. So you know, some
- 27:35Speaker 4: pharmacists will say, okay, I'm going to have like, you know,
- 27:38Speaker 4: these five core team that's going to just kind of
- 27:42Speaker 4: test it out and see how it works for our patient,
- 27:45Speaker 4: to develop a protocol that can then be passed on
- 27:48Speaker 4: to the wider team and they can do the training
- 27:50Speaker 4: and all that. So we don't really dictate that process
- 27:53Speaker 4: how they want to do that. Some we'll just kind
- 27:55Speaker 4: of write off the bat, say well, you've done all
- 27:57Speaker 4: this work to implement it, go ahead and kind of
- 28:01Speaker 4: make it available and then as questions come up, they
- 28:04Speaker 4: can certainly reach out to us and we can you know,
- 28:06Speaker 4: discuss it further. There's always you know, nothing's really perfect
- 28:12Speaker 4: at the time where you you know, make it available.
- 28:15Speaker 4: You were always iterating, We're always you know, taking that
- 28:18Speaker 4: feedback and closely monitoring and adjusting what we need to
- 28:22Speaker 4: just because that's I mean, those are our users. So
- 28:25Speaker 4: we have to listen to the clinicians and make sure
- 28:28Speaker 4: that you know, they're able to use it to the
- 28:31Speaker 4: most optimized manner, you know, in their workflow. So we
- 28:34Speaker 4: want to we're very close to our users and get
- 28:37Speaker 4: their feedback routinely.
- 28:41Speaker 1: Very cool. How does how frequent is the training? What
- 28:46Speaker 1: training resources are available? How do you make sure that
- 28:49Speaker 1: as your app and you know, your technology is updated,
- 28:54Speaker 1: that all of your providers using this are in the now.
- 28:59Speaker 4: Yeah, so, oh that's a great question. We do have
- 29:02Speaker 4: quite an extensive implementation process and in the onboarding you know,
- 29:06Speaker 4: an implementation manager he works closely with like the team
- 29:10Speaker 4: champions and providing a lot of resources as far as training.
- 29:14Speaker 4: So there's the technical training, right like, here's the platform,
- 29:17Speaker 4: here's all the button, this is how you navigate, this
- 29:20Speaker 4: is how you get from one place to another. And
- 29:22Speaker 4: then there's resources available for more clinical protocols and things.
- 29:28Speaker 4: You know, there's and you'll see this if you're working
- 29:32Speaker 4: on a product that you have to kind of balance
- 29:35Speaker 4: not going over that not offering clinical advice and clinical
- 29:40Speaker 4: training because you're you know, representing a product and software.
- 29:45Speaker 4: So that's I will say, that's a challenge for me
- 29:48Speaker 4: because I'm a clinician at heart, so oftentimes like, well,
- 29:51Speaker 4: I would do this, but you know, really there's limitations
- 29:54Speaker 4: of what you can kind of provide as its advice.
- 29:57Speaker 4: So we provide all the resources we can, you know,
- 30:01Speaker 4: from and we're also kind of always updating those because
- 30:06Speaker 4: you know, you train someone and then and then you
- 30:09Speaker 4: get the questions and you think about it and say, hmm,
- 30:11Speaker 4: maybe I should have included this in the training because
- 30:13Speaker 4: we're getting this question often. So we have you know,
- 30:18Speaker 4: kind of live training and video resources within the platform.
- 30:22Speaker 4: We have also developed some competencies that you know, teams
- 30:25Speaker 4: can utilize for their own training purposes. Oftentimes, I would
- 30:29Speaker 4: say ninety percent of the time the sites will take
- 30:33Speaker 4: those and incorporate in some sort of training of their own.
- 30:37Speaker 4: We also have a protocol library that is shared, so
- 30:41Speaker 4: our customers are really generous and they will you know,
- 30:44Speaker 4: it's a collaborative effort, right, So clinicians are. We're very
- 30:48Speaker 4: willing to share information with each other. So oftentimes we
- 30:52Speaker 4: either refer them to you know, a similar site or
- 30:55Speaker 4: a similar challenge they may be having, or maybe maybe
- 30:58Speaker 4: it's a you know, really large system so it's really overwhelming,
- 31:01Speaker 4: so we'll connect them to another user who went through
- 31:04Speaker 4: that process to help them through. We have protocols that
- 31:07Speaker 4: some of our sites have shared with us that they said,
- 31:10Speaker 4: it's fine, you can go ahead and share this with
- 31:12Speaker 4: other other users if they would like. So there's a
- 31:16Speaker 4: lot of different avenues. And then we also have a
- 31:19Speaker 4: support channel, so it's like a chat, but it's you know,
- 31:23Speaker 4: available twenty four seven. It's a human. It's a live
- 31:26Speaker 4: human that we have that is answering those questions. So
- 31:30Speaker 4: anytime that even like throughout the process of implementation or
- 31:34Speaker 4: training or even after they're live, you know, if they
- 31:37Speaker 4: ever have questions, that they can quickly get in touch
- 31:39Speaker 4: with us and ask the questions. Some questions are easy
- 31:43Speaker 4: and we could provide help articles and resources for that,
- 31:46Speaker 4: but some questions require a little bit more. I guess
- 31:49Speaker 4: in depth review and for those you know, usually comes
- 31:53Speaker 4: to me and my science team and will review it
- 31:56Speaker 4: and get back to them as soon as possible, so
- 31:58Speaker 4: lots of resources available, and we're constantly growing that kind
- 32:02Speaker 4: of section to make FAQ articles, Like I guess, continuously
- 32:09Speaker 4: reviewing the inquiries we're getting, and if we notice a trend,
- 32:13Speaker 4: then we'll just go ahead and create a resource or
- 32:15Speaker 4: an FAQ or a help article around that so then
- 32:18Speaker 4: it can be answered easily from the health center versus
- 32:22Speaker 4: somebody you know, having to reach out to us.
- 32:25Speaker 3: I love how much from an innovation standpoint, you are
- 32:29Speaker 3: listening to your user. It's this idea of user design
- 32:33Speaker 3: right user experience that is integral to any product, particularly
- 32:36Speaker 3: when it's software related. But it seems like you guys
- 32:38Speaker 3: are knocking out of the park, so keep it up.
- 32:41Speaker 3: I wanted to transition. I'm passionate about innovation, but I'm
- 32:44Speaker 3: also passionate about education. And I know that dose me
- 32:47Speaker 3: has an educational product as well that I've used with
- 32:51Speaker 3: my students, so I know some of our listeners are
- 32:54Speaker 3: educators or preceptors. So Charmin, could you tell us a
- 32:57Speaker 3: little bit more about that education platform that does me
- 33:01Speaker 3: has created.
- 33:02Speaker 4: Yes, I love that you have used it. It makes
- 33:05Speaker 4: me very happy because it's my goal to kind of
- 33:07Speaker 4: you know, make that available again. The goal is to
- 33:11Speaker 4: get it, you know, get everybody exposed to it. And
- 33:14Speaker 4: we know as pharmacists now like you have to have
- 33:17Speaker 4: it skills if you're going to work in a pharmacy.
- 33:19Speaker 4: You know, it doesn't matter what setting you're in, but
- 33:22Speaker 4: you have to have figure it out. You're going to
- 33:23Speaker 4: be interacting at the very least the EHR, which can
- 33:27Speaker 4: be depending on the EHR, it can be a lot
- 33:29Speaker 4: of tools and you know a lot of things you're
- 33:32Speaker 4: navigating and for sure other software. So one of the
- 33:37Speaker 4: one of the you know questions or queries or inquiries
- 33:42Speaker 4: I receive often from pharmacists is a lot of pharmacists
- 33:45Speaker 4: that aren't just familiar with Bajan dosing or modeling software,
- 33:49Speaker 4: right because this you know, I don't know about you,
- 33:51Speaker 4: but it used to be one of those things that
- 33:53Speaker 4: are special like pharmacologists sort of focused on right now,
- 33:58Speaker 4: It wasn't like kind of mainstream so to speak, in
- 34:01Speaker 4: the clinical workflow. So but these software are becoming more
- 34:05Speaker 4: and more integrated into the workflow. So you know, why
- 34:08Speaker 4: not start at the education because that solves a lot
- 34:11Speaker 4: of probably you know, challenges that pharmacists may see once
- 34:16Speaker 4: they're in practice. So if they're not exposed to it
- 34:18Speaker 4: when they're learning about PK, then how are they going
- 34:21Speaker 4: to really grasp the concept when they're actually practicing. And so,
- 34:26Speaker 4: you know, a lot of European customers of ours do
- 34:29Speaker 4: utilize what we have as a kind of free educational
- 34:32Speaker 4: resource for called the Dosing Institute, So it has some
- 34:36Speaker 4: references and things like that, but also it's like the
- 34:39Speaker 4: educational version of our software. So if you want, if you're, say,
- 34:44Speaker 4: you know, justin you're teaching PK courses and maybe you're
- 34:47Speaker 4: covering the antimicrobial PK UH and you want to demonstrate
- 34:52Speaker 4: how a software can help you do that auc guided dosing,
- 34:56Speaker 4: you can, you know, you usually there's a method of
- 35:00Speaker 4: contacting us. We set it up, set up the access
- 35:03Speaker 4: for the universities, and this is for university settings only
- 35:06Speaker 4: because it's an educational resource so not for clinical care.
- 35:09Speaker 4: And so you can then use it in your lectures
- 35:13Speaker 4: to demonstrate it. You can give you your students a
- 35:17Speaker 4: way to sign up for it, and once they sign up,
- 35:20Speaker 4: you can sign them cases or they can practice doing cases.
- 35:24Speaker 4: So it's really setting them up for like a real
- 35:27Speaker 4: life example. So I think we have I have gotten
- 35:31Speaker 4: more interest and growth in the US, I would say
- 35:34Speaker 4: more and more pharmacies. I guess educators and especially in
- 35:38Speaker 4: those areas where they're dealing with TDM and kind of
- 35:41Speaker 4: teaching those concepts and know that their software that they're
- 35:44Speaker 4: going to be using, they're trying to incorporate it very
- 35:47Speaker 4: in various ways in their curriculums. So yeah, there's definitely
- 35:52Speaker 4: more and more use of that, and I'm happy to
- 35:55Speaker 4: see that, you know, Like you know, I used to
- 35:57Speaker 4: be really involved with residents, training and students, so you know,
- 36:02Speaker 4: that's something that I want to continue to make sure
- 36:04Speaker 4: that we provide the resources for for educators to be
- 36:07Speaker 4: able to utilize. Because once you you know, if you've
- 36:10Speaker 4: seen it in the like, seen it and used it
- 36:13Speaker 4: in cases while you're you know, in pharmacy school, right,
- 36:16Speaker 4: then it becomes easier when you're it's one less thing
- 36:19Speaker 4: to like have to figure out when you're a student
- 36:22Speaker 4: or a resident in that training. So yeah, that's definitely
- 36:26Speaker 4: available and can be utilized by anybody who's who's teaching
- 36:29Speaker 4: at a pharmacy school.
- 36:31Speaker 3: Well, let me just quickly say thank you. It's been
- 36:34Speaker 3: a benefit to our students here at Cedarville University and personally,
- 36:38Speaker 3: we're actually teaching in a new curriculum that has what
- 36:41Speaker 3: we call synthesis weeks in it, and my intention is
- 36:43Speaker 3: to use dose Merx and the educational platform the Dosing
- 36:47Speaker 3: Institute more often because what we're trying to do is
- 36:49Speaker 3: bridge classroom through real life and this is a great
- 36:53Speaker 3: way to do it. So again, just wanted to say, hearty,
- 36:55Speaker 3: thank you for keeping that educational focus on your software.
- 37:01Speaker 4: It's great, that's great, justin, that's great to hear you.
- 37:04Speaker 4: Let me know if you need anything as you're as
- 37:06Speaker 4: you're developing those cases or anything like that, you know,
- 37:09Speaker 4: anything I can do to support that. But it makes
- 37:12Speaker 4: me really happy when I know that somebody is actually
- 37:15Speaker 4: using it and benefiting benefiting from it, because you know,
- 37:18Speaker 4: sometimes you kind of start focusing on just the product
- 37:21Speaker 4: and what you're doing, you know, kind of building with it.
- 37:24Speaker 4: But to see it being used in kind of different environments,
- 37:27Speaker 4: it's it's very awarding.
- 37:30Speaker 1: That's yeah, that's amazing, And just like you're saying, justin,
- 37:33Speaker 1: I feel like maybe it's a good practice to know
- 37:37Speaker 1: how to do the very cumbersome kinetics A couple of
- 37:40Speaker 1: times in your life, but like ideally, like we know
- 37:44Speaker 1: that there's all these products available that are going to
- 37:46Speaker 1: make us more efficient, and then we probably are not
- 37:50Speaker 1: going to do them in real life unless we have
- 37:54Speaker 1: an extra hour or two. Oh god, that was so
- 37:57Speaker 1: painful doing them.
- 37:58Speaker 4: Yeah, early were running after you know, the nurse to
- 38:02Speaker 4: make sure the level is done correctly, and you know,
- 38:05Speaker 4: yeah writing I don't know. I used to have like
- 38:08Speaker 4: these template like paper where I fill in the time
- 38:12Speaker 4: of the dose when you have to do the level.
- 38:14Speaker 4: So yeah, if you don't have to do that, trust me,
- 38:17Speaker 4: you don't. You don't want to because the nurses will
- 38:19Speaker 4: also love you for not bothering them. Yeah.
- 38:22Speaker 1: Amen. So obviously, as I said, we're building out technology
- 38:28Speaker 1: for perfecting feeds and we have a bunch of vendors
- 38:31Speaker 1: we're building on on Salesforce, health Cloud, and one of
- 38:33Speaker 1: the most important things to us, and I'm assuming to
- 38:36Speaker 1: douce me too, is HIPPO compliance because obviously, if you're
- 38:41Speaker 1: able to integrate in the EHRULL pull the patient data,
- 38:46Speaker 1: what are you guys doing as far as hip A
- 38:50Speaker 1: compliance and ensuring that your software is safe?
- 38:56Speaker 4: And you know, data security has become so important, right
- 38:58Speaker 4: especially recently with all the all the things I'm sure
- 39:02Speaker 4: you all read in the news with like all the
- 39:04Speaker 4: cyber attacks and things, so it's really like scrutinized. It's
- 39:08Speaker 4: actually one of the processes that takes quite some time
- 39:11Speaker 4: when we're getting a new customer because the IT team
- 39:14Speaker 4: has to really review all of all our processes, policies
- 39:18Speaker 4: and things like that. We are the only invasion platform
- 39:23Speaker 4: that is high trust are two certified, which is kind
- 39:26Speaker 4: of the highest Level's a lot of work to get done,
- 39:30Speaker 4: but we have it, so that really facilitates the process
- 39:35Speaker 4: and and you know kind of ensuring trust that everything's
- 39:38Speaker 4: secure and we're kind of following the highest compliance policies.
- 39:42Speaker 4: So yeah, that's that covers pretty much all of hip
- 39:45Speaker 4: hop phi how it's handled, because that's you know, really
- 39:49Speaker 4: important because if you can imagine how you know, the
- 39:52Speaker 4: data that is kind of being integrated, it's it's very
- 39:55Speaker 4: important for us to keep on top of that. So
- 39:57Speaker 4: that's what we have for in place for our our platform.
- 40:02Speaker 4: We're also going see you know, we we have ce mark,
- 40:05Speaker 4: which is more for Europe and getting up classified. Europe
- 40:10Speaker 4: is upclassifying it as as a device, so we're going
- 40:14Speaker 4: through that process as well, and that's very it's it's
- 40:19Speaker 4: very very security focus and making sure we have all
- 40:22Speaker 4: the processes in place with you know, ISO and CEE Mark.
- 40:26Speaker 4: So yeah, we were because we have to, you know,
- 40:30Speaker 4: make sure that we're meeting all the regulatory requirements for
- 40:33Speaker 4: so many different countries and parts of the world. It's
- 40:37Speaker 4: it's at the top of our list to make sure
- 40:39Speaker 4: that we're up to date with everything. So yeah, and
- 40:42Speaker 4: High Trust really facilitates with that, or does.
- 40:45Speaker 1: We're in the process now of getting the org HI
- 40:48Speaker 1: trust and it's like a two year, three hun k
- 40:52Speaker 1: minimum journey, so it's no joke. So I have immense
- 40:56Speaker 1: amount of respect for you guys that you went through
- 40:58Speaker 1: that you're on the other side, because even though we're
- 41:01Speaker 1: small and mighty a team of what's going to be
- 41:04Speaker 1: thirty five soon, we still have one full time cybersecurity
- 41:08Speaker 1: person because you can't get around it. And then again,
- 41:12Speaker 1: working with health plans, you guys, work with health systems,
- 41:15Speaker 1: like the high Trust R two is like kind of
- 41:18Speaker 1: your golden ticket once you get there, but it is
- 41:21Speaker 1: it is a lot of work.
- 41:22Speaker 4: So kudos to you.
- 41:23Speaker 1: And the Ghostly team for getting there.
- 41:25Speaker 4: Yeah, it's it's a lot of work, but and then
- 41:28Speaker 4: I promise it'll be it'll be worth it. You may,
- 41:31Speaker 4: you may, you know, think about it on the way
- 41:34Speaker 4: that why am I doing this? But it'll be worth
- 41:36Speaker 4: it because it's I can't see a world where that's
- 41:40Speaker 4: not required, so, you know, especially with everything that's happened recently.
- 41:45Speaker 4: So yeah, I think it's it's just inevitable that everybody
- 41:47Speaker 4: has to get that.
- 41:50Speaker 3: Sure. I mean, I'm curious as we start to wind
- 41:52Speaker 3: down this episode, what does the future of dos me
- 41:55Speaker 3: rex look like from your perspective? And maybe we can
- 41:58Speaker 3: add in the pediatric spin to do you have things
- 42:01Speaker 3: you'd love to see happen that you think would advance
- 42:05Speaker 3: the therapeutic drug monitoring that is provided through your product?
- 42:11Speaker 4: What does the future look like? I want so many
- 42:13Speaker 4: things in the future, so you know, I would love
- 42:16Speaker 4: it if you know, I would love to make sure
- 42:19Speaker 4: that every clinician has has a platform in hand at
- 42:24Speaker 4: the bedside right for dosing, because we have known as
- 42:30Speaker 4: pediatric clinicians that one size doesn't fit all, But it
- 42:32Speaker 4: seems like some other cohort of our population are slow
- 42:39Speaker 4: to get that. But FDA is pushing forward. So that's good. So,
- 42:42Speaker 4: you know, I think we're going to continue to expand
- 42:46Speaker 4: with a lot of these medications as more more, you know,
- 42:50Speaker 4: drug therapies are becoming very complex, right, so it's not
- 42:53Speaker 4: just like you give a dose and it works and
- 42:55Speaker 4: that's it. You know, as I mentioned on cology earlier,
- 42:59Speaker 4: there there's a lot of work being done that in
- 43:02Speaker 4: that space with carte therapy and you know, some of
- 43:06Speaker 4: these other agents that have been used and they are
- 43:08Speaker 4: being used in conjunction with that that you really have
- 43:11Speaker 4: to make sure that you're doing the right thing when
- 43:14Speaker 4: it comes to dosing, because you're not going those are
- 43:17Speaker 4: expensive treatments. You don't you only get one shot, right,
- 43:19Speaker 4: So so my goal is to just continue to expand
- 43:23Speaker 4: in some of those spaces where it's becoming crucial to
- 43:27Speaker 4: make sure that you get the dose right, you know,
- 43:30Speaker 4: and for obvious reasons, and also just making sure with
- 43:34Speaker 4: you know, the variability that's seen with all the other
- 43:37Speaker 4: kind of physiological reasons, why why somebody would need various doses.
- 43:43Speaker 4: I you know, I would love that to have pharmacists,
- 43:48Speaker 4: especially pediatric pharmacists, be utilizing this more and more drugs
- 43:52Speaker 4: because I think we're going to continue to learn and
- 43:55Speaker 4: evolve in how we're utilizing BAJOR modeling and clinical practice.
- 43:59Speaker 4: And you know, one of the areas of focus has
- 44:03Speaker 4: been to incorporate pharmical genomics information because that's also what's
- 44:08Speaker 4: going to you know, hopefully and by view, should become
- 44:12Speaker 4: standard of care. We'll get there. It's a slow process,
- 44:15Speaker 4: but we'll get there. So we've actually started incorporating models
- 44:19Speaker 4: that include pharmical genomics in there because it just gives
- 44:22Speaker 4: again the full picture. Right. So for example, voricanas all
- 44:26Speaker 4: you're starting it, you have the PK model, you have
- 44:28Speaker 4: the pg X information. If you incorporate all that, you'll
- 44:32Speaker 4: just be that much more precise and that means you
- 44:34Speaker 4: get to target sooner. That means you get their dose
- 44:37Speaker 4: appropriate sooner, and you're making sure the patient ultimately the
- 44:40Speaker 4: patient outcome will be better. So, you know, my goal
- 44:43Speaker 4: is just to see what like how else we can
- 44:46Speaker 4: improve on our models and what else we can incorporate
- 44:50Speaker 4: that will be you know, give the most you know,
- 44:53Speaker 4: make sure you're heading in the right direction and give
- 44:56Speaker 4: the most accurate and precise prediction of dosing that we
- 45:00Speaker 4: just didn't have available before. And we have the tools now,
- 45:03Speaker 4: so we just need to continue to expand on those.
- 45:06Speaker 1: This has been fabulous. Thank you. I love the entrepreneurial
- 45:10Speaker 1: spirit in you because that's what gets me excited enough
- 45:14Speaker 1: every morning, and it's been a true pleasure. We so
- 45:19Speaker 1: appreciate your time. If we wanted to find out more,
- 45:23Speaker 1: I've been perusing the beautiful dose to Me website as
- 45:28Speaker 1: a fellow entrepreneur. I'm looking at who's on your board,
- 45:31Speaker 1: your c spee T, how much you guys raise, like
- 45:35Speaker 1: all those things that like just the things that I
- 45:38Speaker 1: think of as you're talking, extremely impressed by your organization.
- 45:43Speaker 1: If they wanted to find out more information outside of
- 45:45Speaker 1: the website, what are some additional ways that they could
- 45:48Speaker 1: get in contact with you and your organization.
- 45:51Speaker 4: Yeah, we're very active on LinkedIn, so feel free to
- 45:55Speaker 4: use that channel. We didn't even get into the advisory
- 45:58Speaker 4: board as you mentioned it, but lots of research happening there,
- 46:02Speaker 4: you know. I can certainly share some links. We actually
- 46:05Speaker 4: just recently did a poster as well at ekmeit and
- 46:08Speaker 4: it was focused on pediatric big data that was like
- 46:11Speaker 4: five thousand patients in that power. So yeah, I think
- 46:16Speaker 4: that would be really great if people more people, more
- 46:19Speaker 4: pediatric clinicians saw that. But yeah, LinkedIn our website, we have,
- 46:23Speaker 4: like I said, a chat functionality, so anybody who contacts
- 46:27Speaker 4: us through that will get somebody live. It's a human,
- 46:31Speaker 4: not a robot. So those are all the ways, all
- 46:35Speaker 4: the ways that we can you know, get back to
- 46:37Speaker 4: you or answer any questions. No, that's so cool.
- 46:40Speaker 1: Well you never get the personalized touched anymore. You just
- 46:43Speaker 1: always assume you're talking to a robot. So again, applaud
- 46:48Speaker 1: you and your team. Well, thank you so much. It's
- 46:51Speaker 1: been an absolute pleasure. Just in any parting words.
- 46:56Speaker 3: Now, I just want to echo thanks to Charmine and
- 46:58Speaker 3: thanks Seanette for joining us. It's always great to have
- 47:00Speaker 3: students behind the scenes. So yeah, it's uh. I just
- 47:04Speaker 3: know a lot of our podcasts we actually have students
- 47:07Speaker 3: as a part of this, so it's great to have you.
- 47:09Speaker 3: So thanks for joining us.
- 47:13Speaker 1: I'm laughing because poor shaw Nick gets thrown into a
- 47:16Speaker 1: board advisory meeting and then followed by a patient and
- 47:20Speaker 1: then a vendor and then we're in a health plan
- 47:23Speaker 1: like it's Russian Roulette every day, right, Shawnette, you never
- 47:26Speaker 1: know what you're showing up Jesus, laughing, hysteric click, all
- 47:31Speaker 1: part of the fun.
- 47:32Speaker 4: You'll be thankful that for that experience one day, trust me.
- 47:38Speaker 1: Well, thank you guys, it's been a true pleasure. If
- 47:40Speaker 1: everyone has a fabulous day.
- 47:42Speaker 4: Thank you.
- 47:43Speaker 2: That's all for today's episode. Thanks for listening, and remember
- 47:46Speaker 2: to subscribe on Apple Podcast and leave us a review.